Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
作者信息
Garca-Doval Ignacio
出版信息
J Am Acad Dermatol. 2004 May;50(5):801; author reply 801-2. doi: 10.1016/j.jaad.2003.10.673.
PMID:15097974
Abstract
摘要
相似文献
1
Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
J Am Acad Dermatol. 2004 May;50(5):801; author reply 801-2. doi: 10.1016/j.jaad.2003.10.673.
2
Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection.
Clin Infect Dis. 2007 Feb 1;44(3):464-5; author reply 465. doi: 10.1086/510749.
3
[Therapy of tuberculosis in the adult].
Med Klin (Munich). 1995 Apr 15;90(4):229-30.
4
Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
Clin Infect Dis. 2004 Jul 15;39(2):289. doi: 10.1086/421783.
5
Completing tuberculosis prophylaxis in jail: targeting treatment and a comparison of rifampin/pyrazinamide with isoniazid regimens.
Int J Tuberc Lung Dis. 2005 Feb;9(2):230; author reply 230-1.
6
Gynaecomastia during antituberculosis chemotherapy with isoniazid.
J Assoc Physicians India. 2008 May;56:390-1.
7
Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: a meta-analysis.
Int J Tuberc Lung Dis. 2006 Oct;10(10):1080-90.
8
The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Clin Infect Dis. 2010 Aug 1;51(3):366-7; author reply 367-8. doi: 10.1086/654806.
9
Update: Fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection.
MMWR Morb Mortal Wkly Rep. 2002 Nov 8;51(44):998-9.
10
Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe?
Am J Respir Crit Care Med. 2003 Mar 15;167(6):809-10. doi: 10.1164/rccm.2301002.
Zotero 插件